Leigh Marcus

3.1k total citations · 2 hit papers
18 papers, 1.6k citations indexed

About

Leigh Marcus is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Leigh Marcus has authored 18 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Pathology and Forensic Medicine and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Leigh Marcus's work include Neuroendocrine Tumor Research Advances (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Genetic factors in colorectal cancer (3 papers). Leigh Marcus is often cited by papers focused on Neuroendocrine Tumor Research Advances (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Genetic factors in colorectal cancer (3 papers). Leigh Marcus collaborates with scholars based in United States, Canada and Australia. Leigh Marcus's co-authors include Richard Pazdur, Steven J. Lemery, Patricia Keegan, Martha Donoghue, Lola A. Fashoyin‐Aje, Marc R. Theoret, Mengdie Yuan, Julia A. Beaver, Soma Ghosh and Lisa Rodríguez and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Leigh Marcus

17 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

2019 789 citations Leigh Marcus, Steven J. Lemery et al. Clinical Cancer Research profile →
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors

2021 330 citations Leigh Marcus, Lola A. Fashoyin‐Aje et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leigh Marcus United States	12	1.1k	488	457	358	311	18	1.6k
Isabelle Soubeyran France	27	844 0.8×	541 1.1×	368 0.8×	622 1.7×	247 0.8×	70	1.8k
Carlo Messina Italy	23	829 0.8×	540 1.1×	459 1.0×	311 0.9×	401 1.3×	102	1.7k
Priyanka Shivdasani United States	9	661 0.6×	664 1.4×	357 0.8×	266 0.7×	253 0.8×	11	1.4k
Jau‐Yu Liau Taiwan	25	841 0.8×	414 0.8×	256 0.6×	408 1.1×	422 1.4×	79	1.7k
Sebastian Aulmann Germany	31	910 0.8×	795 1.6×	667 1.5×	296 0.8×	324 1.0×	74	2.4k
Kevin Norwood United States	22	1.3k 1.2×	504 1.0×	234 0.5×	363 1.0×	779 2.5×	38	1.8k
Jong‐Mu Sun South Korea	25	1.3k 1.2×	1.1k 2.3×	431 0.9×	131 0.4×	237 0.8×	82	2.1k
James Suh United States	21	1.0k 0.9×	820 1.7×	577 1.3×	313 0.9×	331 1.1×	72	1.9k
Kosei Hasegawa Japan	26	1.4k 1.3×	508 1.0×	353 0.8×	333 0.9×	486 1.6×	179	3.0k
Andy Sherrod United States	20	786 0.7×	525 1.1×	109 0.2×	283 0.8×	225 0.7×	39	1.6k

Countries citing papers authored by Leigh Marcus

Since Specialization

Citations

This map shows the geographic impact of Leigh Marcus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leigh Marcus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leigh Marcus more than expected).

Fields of papers citing papers by Leigh Marcus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leigh Marcus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leigh Marcus. The network helps show where Leigh Marcus may publish in the future.

Co-authorship network of co-authors of Leigh Marcus

This figure shows the co-authorship network connecting the top 25 collaborators of Leigh Marcus. A scholar is included among the top collaborators of Leigh Marcus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leigh Marcus. Leigh Marcus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Grandinetti, Cheryl, et al.. (2025). Evolving Standards: Good Clinical Practice Insights from US FDA , MHRA UK , and Health Canada. Clinical Pharmacology & Therapeutics.

Marcus, Leigh, M. Naomi Horiba, Martha Donoghue, et al.. (2022). FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement. Clinical Cancer Research. 29(5). 838–842. 33 indexed citations

Lemery, Steven J., Lola A. Fashoyin‐Aje, Leigh Marcus, et al.. (2022). Development of Tissue-Agnostic Treatments for Patients with Cancer. 6(1). 147–165. 5 indexed citations

Marcus, Leigh, Lola A. Fashoyin‐Aje, Martha Donoghue, et al.. (2021). FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors. Clinical Cancer Research. 27(17). 4685–4689. 330 indexed citations breakdown →

Casak, Sandra J., Leigh Marcus, Lola A. Fashoyin‐Aje, et al.. (2021). FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma. Clinical Cancer Research. 27(17). 4680–4684. 119 indexed citations

Marcus, Leigh, Martha Donoghue, Stephanie Aungst, et al.. (2020). FDA Approval Summary: Entrectinib for the Treatment of NTRK gene Fusion Solid Tumors. Clinical Cancer Research. 27(4). 928–932. 92 indexed citations

Marcus, Leigh, Steven J. Lemery, Patricia Keegan, & Richard Pazdur. (2019). FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clinical Cancer Research. 25(13). 3753–3758. 789 indexed citations breakdown →

Quezado, Martha, Leigh Marcus, Prashant Chittiboina, et al.. (2017). Cushing disease in a patient with multiple endocrine neoplasia type 2B. SHILAP Revista de lepidopterología. 4. 1–4. 17 indexed citations

Marcus, Leigh, Steven J. Lemery, Sachia G. Khasar, et al.. (2017). FDA Approval Summary: TAS-102. Clinical Cancer Research. 23(12). 2924–2927. 35 indexed citations

10.

Lodish, Maya, Alexandra Gkourogianni, Ethan Bornstein, et al.. (2015). Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy. International Journal of Pediatric Endocrinology. 2015(1). 3–3. 8 indexed citations

11.

Shalabi, Haneen, Gilbert Vézina, James L. Rubenstein, et al.. (2015). Prolonged Complete Response in a Pediatric Patient With Primary Peripheral T-Cell Lymphoma of the Central Nervous System. Pediatric Hematology and Oncology. 32(8). 529–534. 2 indexed citations

12.

Akshintala, Srivandana, Leigh Marcus, Katherine E. Warren, et al.. (2015). Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors. Pediatric Blood & Cancer. 62(4). 603–610. 15 indexed citations

13.

Fargo, John H., Michael F. Guerrera, Leigh Marcus, et al.. (2014). Kaposiform lymphangiomatosis: Unifying features of a heterogeneous disorder. Pediatric Blood & Cancer. 62(5). 901–904. 37 indexed citations

14.

Widemann, Brigitte C., Leigh Marcus, Michael J. Fisher, et al.. (2014). Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).. Journal of Clinical Oncology. 32(15_suppl). 10018–10018. 30 indexed citations

15.

Whitlock, James A., Luciano Dalla Pozza, John M. Goldberg, et al.. (2014). Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL). Blood. 124(21). 795–795. 13 indexed citations

16.

Fox, Elizabeth, Brigitte C. Widemann, Meredith K. Chuk, et al.. (2013). Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma. Clinical Cancer Research. 19(15). 4239–4248. 110 indexed citations

17.

Lodish, Maya, Clara C. Chen, Ninet Sinaii, et al.. (2011). ¹¹¹In-Octreotide Scintigraphy for Identification of Metastatic Medullary Thyroid Carcinoma in Children and Adolescents. The Journal of Clinical Endocrinology & Metabolism. 97(2). E207–E212. 10 indexed citations

18.

Marcus, Leigh, Robert L. Murphy, Elizabeth Fox, et al.. (2011). The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates. Cancer Chemotherapy and Pharmacology. 69(1). 247–252. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact